Paul-Ehrlich-Institut at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Paul-Ehrlich-Institut brings 7 presentations to ESGCT 2026 in Hamburg. Its work centres on vectors that deliver genes to chosen cell types in the body, including targeted lentiviral and AAV designs that generate CAR T cells in vivo and fusion proteins that steer lipid nanoparticles. A second strand covers international regulatory harmonisation.
| Organization | ESGCT 2026 Attendance |
|---|---|
Paul-Ehrlich-Institut Langen, Germany | |
German federal agency for vaccines and biomedicines that authorizes gene and cell therapies and researches targeted viral and lipid vectors. | Workshop Tue Oct 27 9:05am–10:45am Targeted lentiviral vectors for in vivo CAR-T cell generation Vectors and delivery (AAV, lentiviral, LNP)Cell therapies and CAR-T Poster Wed Oct 28 1:30pm–3:30pm An Alternative Approach for In Vivo T Cell Activation Talk Wed Oct 28 3:30pm–5:30pm Off-the-shelf CAR T cells through in vivo gene delivery Cell therapies and CAR-TVectors and delivery (AAV, lentiviral, LNP) Poster Thu Oct 29 2:00pm–4:00pm Bispecific DART-AAVs: How to engineer vectors for gene delivery into non-activated T cells Poster Thu Oct 29 2:00pm–4:00pm CD56-targeted AAV vectors for receptor-selective gene delivery into NK cells and muscle cells Talk Fri Oct 30 11:15am–1:00pm Elements and priorities for international regulatory harmonization for ATMPs Manufacturing, CMC and access Talk Fri Oct 30 12:00pm–1:00pm ApoE-DARPin fusion proteins enable selective RNA transfer to target cells by lipid nanoparticles Vectors and delivery (AAV, lentiviral, LNP)RNA and oligonucleotide therapies |
Instantly find 20 buyers from Paul-Ehrlich-Institut
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction